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SURGERY FOR ACQUIRED 
HEART DISEASE 
LONG-TERM RESULTS OF 
VALVE REPLACEMENT WITH 
THE ST. JUDE MEDICAL 
PROSTHESIS 
To assess with truly long follow-up the long-term results of valve replacement with the 
St. Jude Medical prosthesis (St. Jude Medical, Inc., St. Paul, Minn.), we reviewed the 
case histories of the first 1112 patients undergoing 1244 valve replacements with this 
valve between June 12,1978, and June 12,1987:690 male (62%) and 422 female patients, 
mean age 56 years. A total of 773 patients (69%) had the aortic valve replaced, 207 (19%) 
the mitral valve, and 132 (12%) the aortic and mitral valves. There were 42 hospital 
deaths (3.8%). Follow-up was 97.5% complete (8988 patient-years). There were 213 late 
deaths. Ninety-one (43%) were considered valve-related: sudden death, n = 27; 
anticoagulant-related h morrhage, n = 22; thromboembolism, n = 19; prosthetic valve 
endocarditis, n = 13; valve thrombosis, n = 9; and noninfectious perivalvular leak, n = 
1. Overall actuarial survival, including hospital mortality, was 68% - 6% (95% 
confidence limits) 14 years after the operation. Linearized rates of late valve-related 
events were asfollows: thromboembolism, 1.09% per patient-year; anticoagulant-related 
hemorrhage, 0.94% per patient-year; prosthetic valve endocarditis, 0.32% per patient- 
year; valve thrombosis, 0.33% per patient-year; and perivalvular leak, 0.19% per 
patient-year. Actuarial freedom, at 14 years, from thromboembolism was 89% - 3%, 
anticoagulant-related hemorrhage 83% + 8%, valve thrombosis 97% + 1%, and 
reoperation 95% -+ 3%. Actuaria] freedom from all valve-related deaths and valve- 
related morbidity and mortality, at 14 years, was 84% + 6% and 61% - 8%, respectively. 
We conclude that, because of its low thrombogenicity, low incidence of valve-related 
events, and low valve-related mortality, the St. Jude Medical valve is one of the best 
performing mechanical prosthesis currently available. Nevertheless, the late valve- 
related complications and deaths illustrate that the quest for a "perfect" prosthesis 
remains unfulfilled. (J THORAC CARDIOVASC SURG 1995;109:858-70) 
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"ideal" valve and was first used clinically in October 
1977. 2 Because of its attractive characteristics, the 
St. Jude Medical prosthesis was introduced into our 
unit in June 1978 and became the mechanical 
prosthesis routinely used. By the end of October 
1994, 3074 St. Jude Medical valves had been im- 
planted in 2746 patients: 1844 aortic, 574 mitral, and 
328 double aortic and mitral replacements. We 3 
reported our 5½-year experience with the valve in 
1985. 
Despite the low incidence of valve-related prob- 
lems reported in early clinical studies, 2-4 the St. Jude 
Medical valve remains exposed to the usual compli- 
cations of any mechanical valve substitute. 
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Table I. Valve pathophysiologic conditions 
A ortic Mitral 
No. % No. % 
Stenosis 296 32.7 82 24.2 
Regurgitation 384 42.5 158 46.6 
Combined 221 24.4 98 28.9 
Prosthesis replacement 4 0.4 1 0.3 
Total valves 905 100 339 100 
The purpose of this review was to assess long- 
term results in the first 1112 patients undergoing 
1244 valve replacements between June 1978 and 
June 1987 and to evaluate, with a long follow-up, the 
overall valve-related complications and mortality 
associated with the St. Jude Medical valve. 
Patients and methods 
Patients. Between June 12, 1978, and June 12, 1987, 1244 
St. Jude Medical valves were implanted in 1112 patients. A
total of 773 patients (69%) underwent isolated aortic valve 
replacement (AVR), 207 (19%) isolated mitral valve re- 
placernent (MVR), and 132 (12%) double aortic and mitral 
valve replacement (DVR). The series comprised 690 male 
(62%) and 422 female patients (38%), with a mean age of 
55.9 years (fange 9 months to 82 years). Twenty-five patients 
(2.2%) were 15 years or younger and 146 (13%) were aged 
70 years or older. In the AVR group mean age was 57.3 
years, and 122 of these patients (15.8%) were older than 70; 
mean age in the MVR group was 52.9 years, and 15 of them 
(7.2%) were older than 70; and in the DVR group mean age 
was 52.5 years, nine (6.8%) being older than 70 years. Male 
sex predominated in the AVR group (69%) and female sex 
in the MVR and DVR groups (54% and 53.8%, respec- 
tively). Two hundred ten patients (19%) were in atrial 
fibrillation before the operation. Valve pathophysiologic 
conditions are shown in Table I. Of the 384 predominant 
aortic regurgitations, 54 were due to bacterial endocarditis 
and nine to aortic dissection. Of the 158 predominant mitral 
regurgitations, 13were due to bacterial endocarditis. Twelve 
patients had undergone a previous mitral commissurotomy. 
Regarding rereplacement, four patients were reoperated on, 
three for rereplacement of an isolated aortic bioprothesis 
after tissue failure and one for rereplacement of both aortic 
and mitral Edwards-Duromedics bileaflet prostheses (Baxter 
Healthcare Corp., Edwards Div., Santa Ana, Calif.; Hemex 
Scientific, Inc., Austin, Tex.) because of an early prosthetic 
valve endocarditis. Thus four aortic prostheses and one 
mitral prosthesis were replaced by St. Jude Medical valves. 
All patients over 30 years of age had preoperative coronary 
angiography. 
Surgical technique. Cardiopulmonary bypass with 
moderate hypothermia (30 ° C) was performed with a 
disposable bubble or membrane oxygenator. Myocardial 
protection was accomplished by the use of antegrade cold 
potassium crystalloid cardioplegia with topical cooling. 
The mean aortic crossclamp time was 52 minutes for 
AVR, 38 minutes for MVR, and 71 minutes for DVR. The 
Table I I . Operative characteristics 
No. % 
Aortic size (mm) 
19-21 150 16.5 
23-25 441 49 
27-29* 264 29 
31 50 5.5 
Mitral size (mm) 
19-21 1 0.3 
23-25 9 2.7 
27-29 162 48 
31-33 167 49 
Additional procedures 
Coronary artery bypass grafting 94 8.5 
Tricuspid valve repair 20 1.8 
Mitral valve repair 41 3.7 
Septal myectomy 45 4 
Aortic graft 33 3 
Aortic enlargement 9 0.8 
Congenital heart disease 5 0.5 
Ventricular aneurysmectomy 1 
*Includes 11 patients with a 26 mm aortic valve. 
prostheses were anchored to the valve anulus by inter- 
rupted figure-of-eight sutures for AVR and by continuous 
suture for MVR. 
Until 1979, the leaflets of the valve prostheses were 
oriented parallel to the septum in the aortic position and 
parallel to the native leaflets (anatomic orientation) in the 
mitral position. However, anatomic onsiderations and 
consequent hydrodynamic deductions 3'5'6 led us to 
change both these orientations. Prosthetic leaflets are now 
oriented perpendicular to the septum in the aortic posi- 
tion and perpendicular tothe native leaflets (antianatomic 
orientation) in the mitral position. Of the 905 aortic 
prostheses, 705 (78%) were size 23 to 29 mm, and 814 
(90%) were implanted with the prosthetic leaflets ori- 
ented perpendicular to the septum. Of the 339 mitral 
prostheses, 329 (97%) were size 27 to 33 mm, and 312 
(92%) were implanted with prosthetic leaflets in the 
antianatomic orientation. 
Associated surgical procedures were performed in 248 
patients (22%): 201 patients (26%) in the AVR group, 31 
patients (15%) in the MVR group, and 16 patients (12%) 
in the DVR group. Only 94 patients (8.5%) had concom- 
itant coronary atherosclerosis requiring coronary artery 
bypass grafting. Of the nine patients undergoing annular 
or supravalvular enlargement, six patients underwent an 
anulus-enlarging procedure to allow implantation of at 
least a 19 mm prosthesis. Because of good hemodynamic 
performance of the St. Jude Medical valve in small sizes, 7 
annular enlargement was never performed to implant a 
larger valve than sized. Other concomitant procedures are 
listed in Table II. 
Anticoagulant therapy. In 1978, a protocol of early 
anticoagulation involving three steps was initiated8: Inter- 
mittent intravenous injection of heparin (step 1) was 
started during the sixth postoperative hour and relayed 
with subcutaneous calcium heparin (step 2) during the 
twenty-fourth postoperative hour; oral anticoagulation 
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Table III. Hospital mortality (42/ll12 patients =
3.8%) and causes of deaths by valve position 
AVR MVR DVR 
Cause (n = 773) (n = 207) (n = 132) 
Surgical 
Bleeding 3 2 2 
Tamponade 3 
Aortic dissection 1 
Valve-related 
Prosthetic valve infection 1 
Cardiac 
Myocardial failure 4 4 
Infarction 2 1 1 
Complete atrioventricular 2 
block 
Arrhythmia 3 
Noncardiac 
Septicemia 2 1 
Pulmonary failure 1 2 
Cerebral damage 5 1 
Gastrointestinal bleeding 1 
Total 28 (3.6%) 11 (5.3%) 3 (2.3%) 
therapy with warfarin (step 3) was instituted 48 hours after 
the operation, and subcutaneous infusion of calcium 
heparin was continued until the target prothrombin time 
was brought to 1.6 to 1.9 times the control value. In 
addition, special attention was given to fibrinogen level. 
This was measured on the fourth postoperative day and 
then every 2 days, because fibrinogen level only starts to 
rise at this time, reaching sometimes 6,10, or 12 gm/L. To 
counteract this thrombogenic factor, once the fibrinogen 
level exceeds 5 gm/L (normal fibrinogen level 2 to 4 gin/L) 
we routinely use nonsteroidal antiinflammatory drugs 
(NSAIDs), such as diclofenac (50 mg orally per day) or 
ketoprofen (150 mg orally per day), for a mean duration 
of 3 to 5 days, except in patients with a history of gastritis 
or renal insutficiency. NSAID therapy generally is suffi- 
cient to lower the fibrinogen level and allow the optimal 
prothrombin time to be reached faster. Because the 
prothrombin time is an approximate assessment of the 
exact level of anticoagulation required for an individual 
patient, we have used the international normalized ratio 
(INR) since September 1992. According to the anticoag- 
ulation recommendations proposed by Horstkotte and 
associates 9, lo for patients undergoing valve replacement 
with a St. Jude Medical prosthesis, out current target 
INRs are 2.4 to 2.6 for patients with AVR; 2.4 to 2.8 for 
those with MVR in sinus rhythm and with a left atrial size 
less than 30 mm/m2; and 2.7 to 3.1 for those with MVR in 
atrial fibrillation or with a left atrial size larger than 30 
mm/m g. In the first year of our experience, 78 patients 
(AVR, 65; MVR, 10; DVR, 3), all in sinus rhythm, gave 
informed consent o receive an antiplatelet regimen of 
aspirin and dipyridamole only. However, because there 
were four aortic and two mitral thromboses (with two 
deaths) and seven episodes of transient ischemic attack or 
peripheral embolism in this group, all were given antico- 
agulants econdarily. 
Follow-up. Patient follow-up was accomplished by mail 
and/or telephone contact with the referring cardiologist, 
the house physician, the patient, or the family. Follow-up 
data were obtained during a 6-month closing interval 
(May 1993 until the end of October 1993). Of the 1070 
hospital survivors, 27 (2.5%) could not be located and 
were conSidered lost to follow-up. Thus follow-up was 
97.5% complete (1043 patients, mean age at follow-up 
65.5 years). Patient-years of follow-up were 6419 for 
AVR, 1580 for MVR, and 989 for DVR. Total follow-up 
was 8988 patient-years, with a mean follow-up of 117 
months, for a period ranging from 3 to 181 months (the 
very first late death occurred in a patient discharged from 
the hospital 3months earlier). Hospital and late deaths, as 
well as valve-related events, were stringently defined 
according to published Guidelines of The American As- 
sociation for Thoracic Surgery. n
Statistical methods. Actuarial estimates of survival and 
event-free curves for the incidence of thromboembolic 
events, valve thrombosis, anticoagulant-related bleeding, 
and reoperation, as well as for all valve-related deaths and 
all valve-related morbidity and mortality, were calculated 
with the Kaplan-Meier method 12 and reported with 95% 
confidence limits. Patients were censored, withdrawn from 
the study, at the time of replacement of the St. Jude 
Medical valve or at the time of death. Late valve-related 
events defined as embolism, valve thrombosis, anticoagu- 
lant-related bleeding, prosthetic valve endocarditis, para- 
valvular leak in the absence of infection, and pannus 
formation were expressed in linearized form (percent per 
patient-year). Estimates were reported plus or minus the 
standard error of the estimate. Comparisons of curves 
13 14 were made with the log-rank test. ' A Pearson äß test 
was used to seek differences between groups concerning 
hospital and late mortality. 
Results 
Early valve-related events. Early recurrent pros- 
thetic valve endocarditis developed in one patient 
and was fatal despite reoperation. In five patients 
(AVR, 2; MVR, 3; 0.4%), minor clinical hemolytic 
anemia was demonstrated in the early postoperative 
period and resumed spontaneously. In all five cases, 
hemolysis was unrelated to paravalvular leak. Apart 
from these events, no cases of early mechanical 
failure, valve dysfunction, thromboembolic epi- 
sodes, or valve thrombosis were observed. 
Hospital mortality. Forty-two hospital deaths 
(3.8%) occurred, of which only one (2.4%) was 
valve-related. The causes of hospital deaths are 
analyzed in Table III. Apart from one intraoperative 
death resulting from posterior aortic root disrup- 
tion, bleeding of surgical cause and tamponade, 
despite reoperation, were responsible for low output 
state leading to multiorgan failure or brain death. 
Delayed pacing was also responsible for neurologic 
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Table IV. Linearized rate of late valve-related complications 
Valve position All 
Complication Aortic Mitral Double positions 
Embolism 0.84 (54) 1.77 (28) 1.62 (16) 1.09 (98) 
Valve thrombosis 0.25 (16) 0.44 (7) 0.70 (7) 0.33 (30) 
Hemorrhage 0.95 (61) 0.89 (14) 1.01 (10) 0.94 (85) 
Endocarditis 0.30 (19) 0.44 (7) 0.30 (3) 0.32 (29) 
Perivalvular leak 0.18 (12) 0.25 (4) 0.10 (1) 0.19 (17) 
Pannus formation 0.03 (2) 0.00 (0) 0.00 (0) 0.02 (2) 
All complications 2.55 (164) 3.79 (60) 3.74 (37) 2.90 (261) 
Data are shown as percent per patient-year nd (in parentheses) a  number of events. Patient-years of follow-up were 6419 for AVR, 1580 for MVR, and 
989 for DVR (total = 8988 patient-years). 
damage. In three patients having AVR, ventricular 
fibrillation could not be successfully converted to 
sinus rhythm. Finally, of the five patients who died 
of primary cerebral damage in the AVR group, 
three had massive intracranial bleeding on the sec- 
ond postoperative day. These three deaths in pa- 
tients operated on for infective ndocarditis could 
be attributable to the rupture of a concomitant 
mycotic intracranial neurysm. Despite the fact that 
the hospital mortality seemed higher in the MVR 
group than in the AVR or DVR group, no signifi- 
cant difference in hospital mortality according to 
valve location was detected (p = 0.40). 
Late valve-related events. During the period of 
follow-up, 236 patients had 261 valve-related vents 
(linearized rate: 2.90% per patient-year). Some pa- 
tients had more than one complication. Table 1V lists 
the specific valve-related vents and linearized rates. 
Thromboembolism. Ninety-eight thromboembolic 
events occurred in 78 patients (1.09% per patient- 
year): 54 occurred in the AVR group (46 patients, 
1.2 episodes per patient), 28 occurred in the mitral 
group (20 patients, 1.4 episodes per patient), and 16 
occurred in the double valve group (12 patients, 1.3 
episodes per patient). Thirty-five patients had a 
permanent eurologic deficit, which was fatal in 19. 
Of these patients, 27 (77%) were in sinus rhythm 
and eight (23%) were in atrial fibrillation. Forty- 
three patients had a transient ischemic attack (39 
patients) or peripheral embolism (4 patients). Of 
these, 32 (74%) were in sinus rhythm and 11 (26%) 
were in atrial fibrillation. Regarding cardiac rhythm 
according to valve subgroup, 42 of the 46 patients 
with AVR and eight of the 12 with DVR were in 
sinus rhythm, whereas 11 of the 20 patients with 
MVR were in atrial fibrillation. This means that only 
19 patients (24%) were in atrial fibrillation and that, 
in our series, atrial fibrillation did not appear signif- 
icantly associated with thromboembolism. This find- 
ing is confirmed by our early experience with no 
anticoagulation in 78 patients, all in sinus rhythm: 
four embolic episodes were observed in the 65 
patients with AVR and three embolic episodes in 
the 10 with MVR, in addition to valve thrombosis n
six others. 
These embolic omplications occurred at a mean 
delay of 60 months. Transthoracic and, after 1987, 
transesophageal chocardiography were performed 
in most of the 52 patients hospitalized, and a direct 
relation between valve thrombosis and the embolic 
event was detected in only nine of them. The only 
embolic events that could be related to a decrease in
prothrombin time were related to valve thrombosis. 
Most embolic events occurred in patients in whom 
prothrombin time was within the therapeutic range. 
The actuarial freedom from thromboembolic 
complications is shown in Fig. 1. 
Valve thrombosis. Thirty episodes of valve throm- 
bosis (AVR, 18; MVR, 12) occurred in 27 patients 
(0.33% per patient-year). Six of them (AVR, 4; 
MVR, 2) occurred in the group of 78 patients, all in 
sinus rhythm, who were initially not given anticoagu- 
lants. All the others occurred in patients who had a 
history of poor compliance in taking warfarin or, in 
most cases, who discontinued oral anticoagulation, 
resulting in a prothrombin time near 1 at the time of 
valve thrombosis. Five patients died before any 
treatment; nine patients were reoperated on and 
two of them died; and 13 patients were treated with 
fibrinolysis, with two deaths. The actuarial freedom 
from this event is shown in Fig. 2. 
Anticoagulant-related bleeding. Eighty-five patients 
(0.94% per patient-year) had major anticoagulant- 
related hemorrhage n cessitating hospital admission 
or blood transfusion or resulting in death. In all 
patients this complication occurred as a result of 
accidental excessive anticoagulation, and an ele- 
vated prothrombin time was always documented at
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Fig. 1. Actuarial freedom from thromboembolism at 14 years (overall and stratified by valve position). CL, 
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Confidencelimits. 
that time. Twenty-two of these patients died of 
either gastrointestinal bleeding or intracranial hem- 
orrhage (mainly subdural hematoma). 
According to the guidelines, minor bleeding epi- 
sodes were not taken into account. The actuarial 
freedom from this complication is shown in Fig. 3. 
Prosthetic valve endocarditis. Twenty-nine epi- 
sodes of prosthetic valve endocarditis occurred in 27 
patients (AVR, 17; MVR, 7; DVR, 3): 0.32% per 
patient-year. According to valve site, the rate was 
0.30% per patient-year for AVR and DVR and 
0.44% per patient-year for MVR. Thirteen patients 
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had a periprosthetic leakage, which was minor in 
five. Thus eight patients only, with AVR, underwent 
nine reoperations in the acute phase of endocarditis 
for hemodynamic failure, with two deaths. The 
five others, as well as the 14 patients with septi- 
cemia without paravalvular leak or evident clinical 
or echocardiographic involvement of the valve, 
were treated medically. Eleven of these 14 pa- 
tients died, more as a result of septicemia than of 
heart failure. The causative organism was identi- 
fied as Staphylococcus in many of them, Entero- 
coccus in two, Hemophilus in one, and Coryne- 
bacterium in one. Offen blood culture failed to 
identify any causative organism, however, mainly 
in patients having an isolated septicemic syn- 
drome. The mortality of this complication was 
consequently high (48%). 
Paravalvular leak. Noninfectious periprosthetic 
leaks developed in 17 patients (0.19% per patient- 
year). Ten patients had a moderate leak that was 
treated medically. The remaining seven patients 
underwent surgical repair without replacement, with 
one death at reoperation. 
Reoperation. Twenty-eight reoperations were 
performed in 27 patients, with five deaths (18.5%). 
Indications for reoperation i cluded valve thrombo- 
sis in nine patients, prosthetic valve endocarditis in
eight patients, and paravalvular leak in seven pa- 
tients. Two patients in the AVR group were reop- 
erated on for subaortic ring because of fibrous 
pannus formation, and one patient from the DVR 
group underwent heart transplantation for end- 
stage left ventricular dysfunction 12 years later. The 
linearized risk for reoperation was 0.31% per pa- 
tient-year for all patients, and the actuarial estimate 
of the percentage free from reoperation is shown in 
Fig. 4. 
Late deaths and patient survival. Two hundred 
thirteen of 1043 patients (20%) had died by the last 
date of follow-up, at a lineärized rate of 2.4% per 
patient-year. The causes of late deaths, elassified as 
valve-related and non-valve-related, are shown in 
Table V. Two of the late valve-related deaths (one 
sudden death in the AVR group and one mitral 
thrombosis in the DVR group) oecurred in the 78 
patients who were initially not given anticoagulants. 
No significant difference between the different valve 
loeations was detected for valve-related deaths or 
for total late deaths (p = 0.69 and p = 0.37, 
respectively). 
The overall aetuarial patient survivals including 
hospital mortality were 73% and 68% at 11 and 14 
years, respectively (Fig. 5). Actuarial survival ac- 
cording to valve site among the AVR, MVR, and 
DVR groups was not significantly different at 11 
years (74%, 71%, and 69%, respeetively). 
The overall actuarial freedom from all valve- 
related deaths was 89% at 11 years and 84% at 14 
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Table ¥. Late mortality (213/1043 patients = 20%) and causes of deaths by valve position 
Aortic Mitral Double 
(n = 729) (n = 190) (n = 124) 
Cause of death No. % No. % No. % 
Valve-related: 91 (43%) 60 8.2 19 10 12 9.7 
Sudden death 18 2.5 7 3.7 2 1.6 
Thromboembolism (cerebral) 14 1.9 2 1.05 3 2.4 
Anticoagulant-related bleeding 15 2 4 2.1 3 2.4 
Prosthetic valve endocarditis 8 1.1 4 2.1 1 0.9 
Valve thrombosis 4 0.6 2 1.05 3 2.4 
Noninfectious perivalvular leak 1 0.1 
Noù-vaive-related: 122 (57%) 93 12.7 13 6.8 16 12.9 
Cardiac 29 4 8 4.2 6 4.8 
Noncardiac 55 7.5 4 2.1 9 7.3 
Unknown 9 1.2 1 0.5 1 0.8 
Total late deaths 153 20.9 32 16.8 28 22.6 
years (Fig. 6), and the overall freedom from all 
valve-related morbidity and mortality was 70% at 12 
years and 61% at 14 years (Fig. 7). 
At 14 years in DVR recipients there was a slight 
trend toward lower freedom from all valve-related 
morbidity and mortality, as well as lower survival; 
however, even though differences did not reach 
statistical significance (p = 0.3), statistical power of 
this analysis is low because the number of MVR and 
DVR recipients is relatively small, especially at 13 
and 14 years. 
Comparison of New York Heart Association 
functional class before operation and by the last 
date of follow-up in the 830 long-term survivors 
showed that whereas 54% of these patients were in 
class III or IV before the operation, at follow-up 
(minimum 6 years, maximum 15 years), 95% of 
these survivors were in functional class I or II. 
Discussion 
For more than 16 years the St. Jude Medical valve 
has been routinely used in out unit when a mechan- 
ical prosthesis was needed for valve replacement. In
the choice of valve substitutes, mechanical versus 
tissue, two parameters are generally considered a
contraindication for mechanical valve insertion: pre- 
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existing or comorbid conditions and advanced age, 
both predisposing to bleeding when anticoagulants 
are used. All patients were screened before the 
operation to rule out those having any disease likely 
to be responsible for anticoagulant-related bl eding. 
With regard to age, the current increasing life 
expectancy of patients operated on before 75 years 
of age, the poorer durability of bioprostheses, and 
the surgical risk of reoperations in octogenarians 
should be considered, as well as the absence of 
statisticaUy significant differences inthe incidence of 
major anticoagulant-related bleeding in out series 
between patients older than 70 years (11 episodes in 
132 patients, 8.3%) and those younger than 70 years 
(74 episodes in 911 patients, 8.1%) (p = 0.93). Thus 
it appears that "advanced" age did not result in a 
higher ate of bleeding complications. We therefore 
considered that the classic "advanced" age had to be 
extended to 75 years. This policy is supported by 
Kratz and associates, 15 who emphasize that there 
was, in their series, "a trend toward operating on 
older patients a  weil as expanded indications for 
the use of the St. Jude prosthesis nthat age group." 
Moreover, when referring to the other St. Jude 
Medical valve replacement series, 15-19 it appears 
that age range was similar and mean age was slightly 
higher than in out series: 44 of the 1200 patients 
(3.7%) in the series reported by Fernandez and 
associates is were octogenarians. This means that 
many centers also extended the frontier of "ad- 
vanced" age, contraindicating mechanical valve in- 
sertion beyond 70 years. 
One wonders about the true importance of a 
specific orientation of prosthetic leaflets in the 
aortic and mitral positions. Chaux and Blanche, 2° 
and Laub and coworkers 21outlined that the clinical 
performance of the St. Jude Medical valve is excel- 
lent in either orientation and that the prosthesis can 
be oriented in any direction if no subvalvular tissue 
or foreign material is present hat would interfere 
with leaflet motion. However, several factors hould 
be taken into consideration to determine how the 
valve should be placed, according to individual 
patient circumstances. Embolic events and valve 
thrombosis, in our series, occurred in either orien- 
tation, as weil as in the aortic or mitral position. 
However, at the very beginning of our experience, 3 
intraoperative anatomic considerations i  two aortic 
thrombosed valves showed that, in case of excessive 
bulging of a hypertrophied septum, as confirmed by 
Chaux and Blanche, anterior flow could be dis- 
turbed when prosthetic leaflets were oriented paral- 
lel to the septum, which could be an additional 
thrombogenic factor. In the mitral position, our 
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suggestion of antianatomic orientation was also 
founded on intraoperative considerations, 3 because 
it appears that with the anatomic orientation the 
posterior leaflet in the open position is close to 
the left ventricular wall. Thus the posterior area of 
the prosthesis is less likely to allow as free flow 
as the anterior area. These theoretic onsiderations 
have been supported by many authors: Asyn- 
chronous leaflet closure was found echocardio- 
graphically to be reduced in valves implanted in 
the antianatomic orientation. 22' 23 Duncan and col- 
leagues 24 found that the theoretic advantages of this 
proposed orientation appeared sound and adopted 
its use. More recently, Laub and colleagues 21con- 
firmed experimentally that "on average the clear- 
ance was 59.2% larger with the valve oriented 
antianatomically" and concluded that "there is evi- 
dence to support hat this [anatomic orientation] is
not the ideal orientation." Thus, in our opinion, the 
main advantage ofthese proposed orientations con- 
sists in optimizing the hydrodynamic performance of
the valve more than avoiding leaflet impingement, 
because the St. Jude Medical valve is really the 
bileaflet prosthesis exhibiting the lowest profile. 
Potential impingement risk is low and, whatever the 
valve size, was never observed. 
The rate of concomitant aorta-coronary b pass 
grafting (8.5%) was lower than in the other eported 
serieslS-lS, 24 (16% to 48%). Because all our patients 
older than 30 years of age underwent coronary 
angiography, this finding could be due to the fact 
that our patient population is almost exclusively 
referred from the southwestern part of France, in 
which epidemiologic studies uggest that the popu- 
lation is less likely to have early atheromatous 
coronary artery disease. Most of our patients with 
coronary disease are older than 70 years of age. 
Our operative mortality of 3.8% did not differ 
from that in our previous report and compares 
favorably with that reported for the St. Jude Medical 
valve 15-19 and other mechanical prosthesesY -2s 
Regarding the rate of late deaths, late mortality, 
since our previous report, increased from 6.3% at 
51/2 years to 20% at 14 years, with an incidence of 
valve-related deaths increasing from 34% to 43%. 
However, the linearized incidence of late deaths 
(2.4% per patient-year) with a mean follow-up of 
9.75 years is almost identical to that reported by 
Ibrahim and coworkers 19 but appears to be lower 
than that reported in other series (4.53% to 6.6% 
per patient-year). 15-18 Because the strongest risk 
factor for late death is the presence and extent of 
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associated coronary atherosclerosis, the low inci- 
dence of concomitant coronary disease in our pa- 
tients could explain this difference. This study re- 
vealed that the most frequent late valve-related 
events were thromboembolism (1.09% per patient- 
year) and hemorragic omplications related to anti- 
coagulants (0.94% per patient-year). These events 
represented 38% and 33% of late events, respec- 
tively, and were responsible for 9% and 10% of late 
valve-related deaths, respectively. In fact, incidence 
of thromboembolism compares with other series of 
St. Jude Medical valves 15-a9' 24 (0.8% to 3.5% per 
patient-year), but appears lower than that reported 
for other mechanical and/or porcine prostheses by 
Orszulak, z5 Daenen, 28 and their associates (2.5% to 
4.6% per patient-year). Most instances of major 
anticoagulant-related bleeding occurred many 
months or years after the operation in patients in 
whom comorbid conditions developed, such as du- 
odenal or gastric ulcer or gastrointestinal carcinoma 
nonexistent at preoperative screening. In addition, 
bleeding was always favored by an elevation of 
prothrombin time rar above the therapeutic range. 
When these bleeding complications are evaluated in 
elderly patients, it appears that there was no differ- 
ence in the incidence of anticoagulant-related late 
deaths in the three groups: AVR 2%, MVR 2.1%, 
and DVR 2.4%, despite the fact that 15.8% of 
patients in the AVR group were older than 70 years 
(versus 7.2% in the MVR and 6.8% in the DVR 
group). Moreover, the linearized rate of hemor- 
rhage was similar in the three groups (0.95%, 
0.89%, and 1.01% per patient-year, espectively). 
Finally, as mentioned previously, there was no sta- 
tistically significant difference in the number of 
major bleeding episodes in patients older or younger 
than 70 years of age. Comparison of the overall 
incidence of anticoagulant-related bleeding in our 
series (0.94% per patient-year) was similar to that 
reported by Fernandez and associates 18(0.95% per 
patient-year), higher than that reported by Arom and 
colleagues 17 (0.56% per patient-year), and lower 
than that reported by Duncan, 24 Czer, 16 Kratz, 15 and 
their colleagues (1.13% to 2.89% per patient-year). 
When valve thrombosis occurred, a decreased 
prothrombin time, near 1, was always documented. 
This serious complication carried a mortality of 33% 
in our series. To manage this complication, we 
rapidly used fibrinolytic treatment with streptoki- 
nase and/or urokinase in 13 patients. The treatment 
was successful in 11 patients, whereas two of the 
nine patients who underwent reoperation died. 
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From our experience with fibrinolytic treat- 
ment, 29-32 our current opinion is that the prostheses 
most likely to be treated by fibrinolysis are those in 
the aortic position. Usually only one leaflet is 
blocked, so that there is sufficient residual flow to 
allow a sufficient amount of fibrinolytic agent to 
reach the thrombosed valves. To the contrary, in 
mitral thrombosis, both leaflets are generally com- 
pletely blocked, resulting in a low output state with 
shock. Thus fibrinolysis is systematically and rou- 
tinely used as the only treatment of thrombosed 
aortic mechanical valves, but surgical intervention 
should be proposed in thrombosed mitral prosthe- 
ses .  
Incidence of prosthetic valve endocarditis n out 
series (0.32% per patient-year) also compares with 
that of others 15'16' 18,z4 (0.16% to 1.13% per pa- 
tient-year) and carries a similar high mortality, 
despite antibiotic treatment and surgical interven- 
tion. 
Late clinical hemolysis did not occur in our prac- 
tice. However, five patients were concerned in the 
early postoperative p riod by an association of slight 
jaundice and anemic syndrome unrelated to para- 
valvular leak. It was an uncommon complication 
that could be due, as emphasized by Arom and 
colleagues, 17either to previous unapparent or hid- 
den hemolytic disease or, more probably, to "spon- 
taneous hemolysis of lethal or sublethal red blood 
cell damage caused by extracorporeal circulation." 
As rar as biologic hemolysis is concemed, 94 pa- 
tients operated on starting in June 1978, and without 
clinical evidence of hemolysis were systematically 
submitted 5 to 19 months after operation to blood 
testing so that the risk of hemolysis could be as- 
sessed. Our results reported in 198133 showed that 
reticulocyte count, platelet count, hemoglobin level, 
and bilirubin level were unchanged from preopera- 
tive values, but haptoglobin level was below normal 
and total and fractionated lactic dehydrogenase 
levels were slightly elevated (250 IU/L), suggesting 
subclinical hemolysis despite intact function of the 
St. Jude Medical prosthesis. In addition, red cell 
filterability was also found to be impaired (filtration 
time increase). 
Over a 16-year experience, no early or late struc- 
tural dysfunction of the valves was observed. The 
long-term durability of the St. Jude Medical valve, 
emphasized by many authors, is best illustrated by 
absence of any measurable wear for any part of the 
critical pivot area or device deterioration i two St. 
Jude Medical prostheses (aortic, size 26 mm, and 
mitral, size 31 mm) explanted from a patient under- 
going heart transplantation 12 years after DVR. 
The only critical remaining problem is the preva- 
lence of systemic embolism and anticoagulant-re- 
lated hemorrhage. These complications could be 
reduced according to the concept of risk-adjusted 
intensity of oral anticoagulation developed by But- 
chart and coworkers 34 to reach an effective degree 
of anticoagulation i the individual patient and a 
lower risk of bleeding complications. Since Septem- 
ber 1992, our experience with lowering the intensity 
of anticoagulation with target INRs ranging from 
2.4 to 3.1 indicated that revision of anticoagulation 
management proposed by Horstkotte did not in- 
crease the risk of thromboembolism and valve 
thrombosis but did reduce bleeding complications. 
The results of our long-term experience with the 
St. Jude Medical valve have been corroborated by 
many authors: this valve is one of the best perform- 
ing mechanical prosthesis currently available and 
thus can be considered as an advance in cardiac 
valve replacement. Nevertheless, even though the 
St. Jude Medical valve satisfied most of the features 
of an excellent mechanical valve substitute, the late 
valve-related complications and deaths illustrate 
that our quest for a "perfect" prosthesis remains 
unfulfilled. 
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assistance in the preparation of the manuscript and illus- 
trations. 
REFERENCES 
1. Kalke BR, Lillehei CW, Kaster RL. Evaluation of a 
double-leaflet prosthetic heart valve of new design for 
clinical use. In: Brewer LA, ed. Prosthetic heart 
valves. Springfield, II1.: Charles C Thomas, 1969:285- 
302. 
2. Nicoloff DM, Emery RW, Arom KV, et al. Clinical 
and hemodynamic results with the St. Jude Medical 
cardiac valve prosthesis. J THORAC CARDIOVASC SURG 
1981;82:674-83. 
3. Baudet EM, Oca CC, Roques XF, et al. A 51/2-year 
experience with the St. Jude Medical cardiac valve 
prosthesis. J THORAC CARDIOVASC SURG 1985;90:137- 
44. 
4. Chaux A, Gray R J, Matloff JM, Feldman H, Sustaita 
H. An appreciation of the new St. Jude valvular 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 5 
Baudet et al. 8 6 9 
prosthesis. J THOP, AC CARDIOVASC SURG 1981;81:202- 
11. 
5. Baudet EM. Cardiac valve replacement with the St. Jude 
Medical prosthesis. Proceedings of the First European 
Symposium on the St. Jude valve, Paris, France, June 
1980. St. Paul: St. Jude Medical, Inc., 1980:1-10. 
6. Baudet EM. Our experience concerning orientation 
of the St. Jude Medical prosthesis: a suggestion for a 
specific orientation in aortic and mitral position. 
Proceedings of the Second International Symposium 
on the St. Jude valve, Sah Diego, March 1981. St. 
Paul: St. Jude Medical, Inc., 1981:9-10. 
7. Wortham DC, Tri TB, Bowen TE. Hemodynamic 
evaluation of the St. Jude Medical valve prothesis in 
the small aortic anulus. J THORAC CARDIOVASC SUR6 
1981;81:615-20. 
8. Baudet EM. Anticoagulation and prosthetic heart 
valves. In: Horstkotte D, Loogen F, eds. Update in 
heart valve replacement. Proceedings of the Second 
European Symposium on the St. Jude Medical heart 
valve, Düsseldorf, Germany, February 1984. New 
York: Springer-Verlag, 1986:109-15. 
9. Horstkotte D, Bergemann R, Althaus U, et al. Ger- 
man experience with low intensity anticoagulation 
(GELIA): protocol of a multi-center randomized, 
prospective study with the St. Jude Medical valve. 
J Heart Valve Dis 1993;2:411-9. 
10. Horstkotte D, Schulte H, Bircks W, Strauer B. Unex- 
pected findings concerning thromboembolic compli- 
cations and anticoagulation after complete 10 year 
follow-up of patients with St. Jude Medical prosthe- 
ses. J Heart Valve Dis 1993;2:291-301. 
11. Edmunds LH Jr, Clark EC, Cohn LH, Miller DC, 
Weisel RD. Guidelines for reporting morbidity and 
mortality after cardiac valvular operations. J THORAC 
CARDIOVASC SURG 1988;96:351-3. 
12. Kaplan EL, Meier P. Nonparametric estimation from 
incomplete observations. J Am Stat Assoc 1958;53: 
457-81. 
13. Mantel N. Evaluation of survival data and two new 
rank order statistics arising in its consideration. Can- 
cer Chemother Rep 1966;50:163-70. 
14. Cox DR. Regression models and life-tables (with 
discussion). J R Stat Assoc (B) 1972;34:187-220. 
15. Kratz JM, Crawford FA Jr, Sade RM, Crumbley AJ, 
Stroud MR. St. Jude prosthesis for aortic and mitral 
valve replacement: a ten-year experience. Ann Thorac 
Surg 1993;56:462-8. 
16. Czer LSC, Chaux A, Matloff JM, et al. Ten-year 
experience with the St. Jude Medical valve for pri- 
mary valve replacement. J THORAC CARDIOVASC SURG 
1990;100:44-55. 
17. Arom KV, Nicoloff DM, Kersten TE, Northrup WF, 
Lindsay WG, Emery RW. Ten years' experience with 
the St. Jude Medical valve prosthesis. Ann Thorac 
Surg 1989;47:831-7. 
18. Fernandez J, Laub GW, Adkins MS, et al. Early and 
late-phase events after valve replacement with the St. 
Jude Medical prosthesis in 1200 patients. J THORAC 
CARDIOVASC SURG 1994;107:394-407. 
19. Ibrahim M, O'Kane H, Cleland J, Gladstone D, 
Sarsam M, Patterson C. The St. Jude Medical pros- 
thesis: a thirteen-year experience. J THORAC CARDIO- 
VASC SURG 1994;108:221-30. 
20. Chaux A, Blanche C. Technical aspects of valvular 
replacement with the St. Jude prosthesis. J Cardiovas- 
cular Surg 1987;28:363-8. 
21. Laub GW, Muralidharan S, Pollock SB, Adkins MS, 
McGrath LB. The experimental relationship between 
leaflet clearance and orientation of the St. Jude 
Medical valve in the mitral position. J THORAC CAm 
DIOVASC SURG 1992;103:638-41. 
22. Duveau D, Michaud JL, Despins P, et al. Mitral valve 
replacement with the St. Jude Medical prosthesis: 242 
cases, with clinical results and an evaluation of pros- 
thesis positioning. In: DeBakey ME, ed. Advances in 
cardiac valves, clinical perspectives. Proceedings of 
the Third International Symposium on the St. Jude 
valve, Scottsdale, Ariz., November 1982. New York: 
Yorke Medical Books, 1983:183-90. 
23. Feldman HJ, Gray RJ, Chaux A. Non invasive in vitro 
and in vivo study of the St. Jude mitral valve prosthe- 
sis. Am J Cardiol 1982;49:1101-9. 
24. Duncan JM, Cooley DA, Reul G J, et al. Durability 
and low thrombogenicity of the St. Jude Medical 
valve at 5-year follow-up. Ann Thorac Surg 1986; 
42:50Õ-5. 
25. Orszulak TA, Schaft HV, DeSmet JM, Danielson GK, 
Pluth JR, Puga FJ. Late results of valve replacement 
with the Björk-Shiley valve (1973 to 1982). J THORAC 
CARDIOVASC SURG 1993;105:302-12. 
26. Vallejo JL, Gonzalez-Santos JM, Albertos J, et al. 
Eight years' experience with the Medtronic-Hall valve 
prosthesis. Ann Thorac Surg 1990;50:429-36. 
27. de Luca L, Vitale N, Giannolo B, Cafarella G, Piazza 
L, Cotrufo M. Mid-term follow-up after heart valve 
replacement with Carbomedics bileaflet prostheses. J 
THORAC CARDIOVASC SURG 1993;106:1158-65. 
28. Daenen W, Nevelsteen A, ran Cauwelaert P, de 
Maesschalk E, Willems J, Stalpaert G. Nine years' 
experience with the Björk-Shiley prosthetic valve: 
early and late results of 932 valve replacements. Ann 
Thorac Surg 1983;35:651-63. 
29. Ledain L, Lorient-Roudaut MF, Gateau P, et al. 
Fibrinolytic treatment of prosthetic heart valves. Eur 
Heart J 1982;3:371-81. 
30. Ledain L, Gateau P, Colle JP, Baudet E, Page A, 
Besse P. Fibrinolytic treatment of prosthetic valve 
thrombosis [Abstract]. Am J Cardiol 1982;49:938. 
31. Ledain LD, Ohayon JP, Colle JP, Lorient-Roudaut 
FM, Roudaut RP, Besse PM. Acute thrombotic ob- 
struction with disc prostheses: diagnostic onsider- 
870 Baudet et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
May 1995 
ations and fibrinolytic treatment. J Am Coll Cardiol 
1986;7:743-51. 
32. Roudaut R, Labbe T, Lorient-Roudaut MF, et al. 
Mechanical cardiac valve thrombosis. Is fibrinolysis 
justified? Circulation 1992;86(Suppl):II8-15. 
33. Baudet E, Fel G, Roudaut R, Gibson D, Roques X, 
Garbe JF. Cardiac valve replacement with the St. 
Jude Medical prosthesis: clinical, echocardiographic, 
and biological results. In: Bircks W, Ostermeyer J, 
Schulte HD, eds. Cardiovascular surgery 1980. Berlin: 
Springer Verlag, 1981. 
34. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM. 
Adjusting anticoagulation to prosthesis thromboge- 
nicity and patient risk factors. Circulation 1991; 
84(Suppl):III61-9. 
Discussion 
Dr. Kit V. Arom (Minneapolis, Minn.). This study has 
again confirmed that the patients who received St. Jude 
Medical prostheses are doing well after 10 years but 
thromboembolism and anticoagulant-related h morrhage 
are still the main concerns. 
I have a couple of questions, Dr. Baudet: You did not 
mention the method of follow-up of these patients. As you 
know, complications related to these particular valves are 
dependent on the anticoagulation level; however, the INR 
is the better method to describe the mean anticoagulation 
level, not PTR or prothrombin time ratio. Which method 
did you use? If you used the PTR, have you converted the 
PTR to INR? If you did, what is the recommended INR 
for the St. Jude Medical prosthesis, both in the mitral and 
in the aortic position? 
My second question has to do with stroke risk factors. 
Many of the emboli may not arise from the prosthesis 
itself, and stroke risk factors may play a significant role in 
this complication. Have you analyzed the embolic rate 
according to the stroke risk factors, for example, in the 
presence of atrial fibrillation and enlarged left atrium? If 
you did, have you seen more stroke or embolism in this 
particular subset han you reported? 
Dr. Baudet. Thank you, Dr. Arom, for your kind 
comments. To answer your first question concerning 
our anticoagulation management, since 1978 we have 
used an early anticoagulation protocol involving three 
steps: intermittent intravenous heparin injection is used 
from the sixth postoperative hour, relayed by subcuta- 
neous calcium heparin at the twenty-fourth hour. Oral 
anticoagulation is instituted 48 hours after the opera- 
tion, and subcutaneous calcium heparin is maintained 
until the target prothrombin time is 1.5 of the control 
value. In addition, if the fibrinogen level increases, 
which we consider to be a thrombogenic factor, we 
would use an NSAID for 3 to 5 days to normalize 
fibrinogen level. As far as long-term anticoagulation is 
concerned, we now follow Horstkotte's rules using the 
INR, with target INRs of 2.4 to 2.6 for patients with 
aortic prostheses, 2.4 to 2.8 for those with mitral 
prostheses who are in sinus rhythm and have a left atrial 
diameter smaller than 26 mm/m 2, and 2.7 to 3.1 for 
patients with mitral prostheses who are in atrial fibril- 
lation with a left atrial diameter larger than 30 mm/m 2. 
In response to your second question regarding the 
stroke risk factors, preoperatively 19% of patients were in 
atrial fibrillation. Among the 78 patients who had postop- 
erative thromboembolic complications, mainly neurologic 
deficits, only 19 also had atrial fibrillation. 
